Liew et al 2018 (Figure 2)

Figure 2. Summary of efficacy and safety of a ritonavir-boosted protease inhibitor plus
lamivudine or tenofovir disoproxil fumarate (two-drug regimen [2DR]) versus three-drug
regimen (3DR).

Figure 2. Summary of efficacy and safety of a ritonavir-boosted protease inhibitor plus
lamivudine or tenofovir disoproxil fumarate (two-drug regimen [2DR]) versus three-drug
regimen (3DR).